Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Have received at least 3 prior lines of therapy, including a proteasome inhibitor \[PI\] and an immunomodulatory agent \[IMiD\] OR have disease that is double refractory to a PI and IMiD~* More than 12 weeks post-transplant of your own blood forming stem cells (autologous transplant)~* Have detectable disease measured by a specific protein in your blood and/or urine~* Must consent to bone marrow aspirate or biopsy.~Exclusion Criteria:~* Solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia, or monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), primary amyloidosis, Waldenstrom's macroglobulinemia, POEMS syndrome or active plasma cell leukemia~* Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti CTLA 4, or anti-CD38 antibody, or allogeneic stem cell transplantation~* Seropositive for human immunodeficiency virus (HIV), Hepatitis B surface antigen or Hepatitis C antibody positive (except if HCV-RNA negative), or history of active chronic hepatitis B or C~* History of central nervous system involvement or symptoms suggestive of central nervous system involvement by multiple myeloma~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab monotherapy (Dose Escalation) (Type: EXPERIMENTAL): Nivolumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort
- Nivolumab + Ipilimumab (Type: EXPERIMENTAL): Nivolumab and Ipilimumab solution intravenously as specified~Non-randomized~Enrollment is closed for this cohort
- Nivolumab + Lirilumab (Type: EXPERIMENTAL): Non-randomized~Nivolumab: 3 mg/kg given every 2 weeks Lirilumab: 3 mg/kg given every 4 weeks~Enrollment is closed for this cohort
- Nivo + Dara + Pom + Dexa vs. Nivo + Dara (Type: EXPERIMENTAL): Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2-6: 240 mg Days 1, 15 Cycle 7 \& beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 \& beyond: 16 mg/kg Day 1~Pomalidomide:~4 mg po (by mouth) daily on Days 1 - 21 of each 28-day cycle~Dexamethasone:~Weeks without daratumumab dosing:~* 40 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants ≤ 75 years old~* 20 mg po daily (Days 1, 8, 15, 22) of each 28-day cycle for participants \> 75 years old~Weeks with daratumumab dosing:~* 20 mg iv before the daratumumab infusion and 20 mg po after the daratumumab infusion in participants ≤ 75 years old~* 16 mg iv before the daratumumab infusion and 4 mg po after the daratumumab infusion in participants \> 75 years old~Enrollment is closed for this cohort
- Daratumumab vs. Nivolumab + Daratumumab (Type: EXPERIMENTAL): Randomized~Nivolumab:~Cycle 1: 240 mg Day 15 Cycle 2 \& beyond: 480 mg Day 1~Daratumumab:~Cycle 1-2: 16 mg/kg Days 1, 8, 15, 22 Cycle 3-6: 16 mg/kg Days 1, 15 Cycle 7 \& beyond: 16 mg/kg Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete